Alnylam Pharmace. buy Citigroup Inc.
Summary
This prediction is currently active. Since the start of the prediction for Alnylam Pharmace. the price has only changed by 0.88%. This prediction currently runs until 16.02.25. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | -1.007% | -1.007% |
iShares Core DAX® | 0.051% | 5.593% |
iShares Nasdaq 100 | 1.808% | 7.445% |
iShares Nikkei 225® | 2.181% | 2.815% |
iShares S&P 500 | 1.040% | 4.975% |
Comments by Citigroup_Inc_ for this prediction
In the thread Alnylam Pharmace. diskutieren